Utama › Sindrom Mielodisplastik › Kansas

Kajian klinikal Sindrom Mielodisplastik di Kansas

5 kajian untuk Sindrom Mielodisplastik sedang mencari peserta di lokasi di Kansas.

Bandar di Kansas

Teks kajian rasmi (Bahasa Inggeris)

Testing the Addition of an IDH2 Inhibitor, Enasidenib, to Usual Treatment (Cedazuridine-Decitabine) for Higher-Risk Myelodysplastic Syndrome (MDS) With IDH2 Mutation (A MyeloMATCH Treatment Trial)

University of Kansas Clinical Research Center, Fairway
University of Kansas Cancer Center, Kansas City
University of Kansas Hospital-Westwood Cancer Center, Westwood

Mengambil pesertaFasa 2

Umur 18 ke atas · Semua jantina · Dikemas kini 2 Okt 2026 · NCT06577441

MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)

University of Kansas Clinical Research Center, Fairway
HaysMed, Hays
University of Kansas Cancer Center, Kansas City
dan 7 lagi

Mengambil pesertaFasa 2

Umur 18 ke atas · Semua jantina · Dikemas kini 25 Sep 2026 · NCT05564390

A Study of GLB-001 in Patients With Relapsed or Refractory Acute Myeloid Leukemia or Relapsed or Refractory Higher Risk Myelodysplastic Syndromes

University of Kansas Medical Center Research Institute, Inc., Kansas City

Mengambil pesertaFasa 1

Umur 18 ke atas · Semua jantina · Dikemas kini 13 Apr 2026 · NCT06146257

Expanded/Activated Gamma Delta T-cell Infusion Following Hematopoietic Stem Cell Transplantation and Post-transplant Cyclophosphamide

University of Kansas Cancer Center, Westwood

Mengambil pesertaFasa 1

Umur 18 hingga 65 · Semua jantina · Dikemas kini 25 Mac 2026 · NCT03533816

Study in Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome Patients to Determine the Recommended Dose of CYAD-02

University of Kansas Cancer Center, Fairway

Mengambil pesertaFasa 1

Umur 18 ke atas · Semua jantina · Dikemas kini 9 Jun 2020 · NCT04167696

Daripada ClinicalTrials.gov, data diperoleh pada 5 Okt 2026. Setiap kajian menetapkan kriteria kelayakannya sendiri; pasukan kajian menentukan siapa yang layak menyertai.